TD Cowen Downgrades Marinus Pharma to Hold
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome has downgraded Marinus Pharma (NASDAQ:MRNS) from Buy to Hold, indicating a more cautious outlook on the stock.
October 25, 2024 | 6:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen analyst Joseph Thome downgraded Marinus Pharma from Buy to Hold, suggesting a more cautious stance on the stock.
The downgrade from Buy to Hold by a reputable analyst like Joseph Thome at TD Cowen suggests a less optimistic view on Marinus Pharma's short-term prospects. This could lead to a negative impact on the stock price as investors may adjust their positions based on this new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100